TMCnet News
Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/jttbnt/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022" report to their offering. The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most sgnificant has been the inclusion of males in routine vaccine recommendations in some countries. Scope
Reasons to buy
Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Vaccination Recommendations and Coverage Rates 5 Competitive Assessment 6 Unmet Need and Opportunity 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/jttbnt/pharmapoint
|